GF
JNCE

Gabelli Funds’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Gabelli Funds’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-526,281
Closed -$974K – 1200
2023
Q1 		$974K Buy
+526,281
New +$652K 0.01% 803

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Gabelli Funds's JNCE Position: Q2 2023 in Review

Gabelli Funds sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 526,281 shares — an estimated $974K sold.

Gabelli Funds first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $974K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Gabelli Funds reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Gabelli Funds sold 526,281 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $974K.
  • Gabelli Funds first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Gabelli Funds's Jounce Therapeutics, Inc. Common Stock position peaked at $974K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Gabelli Funds's 13F filing for Q2 2023, filed 10 Aug 2023.